...
首页> 外文期刊>Trials >Cognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trial
【24h】

Cognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trial

机译:早期痴呆患者的认知辅助与常规治疗相比(痴呆早期认知新试验(DESCANT)):一项随机对照试验的研究方案

获取原文
           

摘要

There is a growing need for an evidence-based approach to home support for people with dementia and their carers following diagnosis but research on the effectiveness and cost-effectiveness of different approaches is sparse. The Dementia Early Stage Cognitive Aids New Trial (DESCANT) will evaluate the clinical and cost-effectiveness of a range of memory aids, training and support to people with mild to moderate dementia and their carers at home and compares that intervention with treatment as usual. This is a multi-site, pragmatic randomised trial preceded by a feasibility study and internal pilot. We aim to allocate at random 360 pairs comprising a person with mild to moderate dementia and an identified carer between the DESCANT intervention and treatment as usual. We assess participants at baseline, 13 and 26?weeks. The primary outcome measure is the Bristol Activities of Daily Living Scale; other participant outcomes include cognition, quality of life, activities of daily living and social networking; carer outcomes include quality of life, sense of competence and mental health. To enhance this quantitative evaluation we are conducting a qualitative component and a process evaluation to assess the implementation process and identify contextual factors associated with variation. The DESCANT intervention reflects current policy to enhance the capabilities of people with dementia after diagnosis and their carers. If it is clinically and cost-effective, its modest nature and cost will enhance the likelihood of it being incorporated into mainstream practice. Current Controlled Trials, ISRCTN12591717 . Registered on 29 July 2016. Protocol number: 31288: North West - Haydock Research Ethics Committee, 20/06/2016, ref.: 16/NW/0389.
机译:诊断后,越来越需要基于证据的方法来为痴呆症患者及其护理人员提供家庭支持,但是对各种方法的有效性和成本效益的研究很少。痴呆早期认知新疗法试验(DESCANT)将评估一系列记忆辅助,对轻度至中度痴呆症患者及其家属的培训和支持的临床效果和成本效果,并将该干预措施与常规治疗进行比较。这是一项多地点,务实的随机试验,然后进行可行性研究和内部试验。我们的目标是在DESCANT干预和常规治疗之间随机分配360对,其中包括轻度至中度痴呆症患者和确定的护理者。我们在基线的13周和26周评估参与者。主要结果指标是布里斯托尔日常生活活动量表;参与者的其他结果包括认知,生活质量,日常生活活动和社交网络;照顾者的结果包括生活质量,能力意识和心理健康。为了加强这种定量评估,我们正在进行定性部分和过程评估,以评估实施过程并确定与变化相关的背景因素。 DESCANT干预措施反映了当前的政策,以提高诊断后痴呆症患者及其护理人员的能力。如果它在临床上具有成本效益,那么其适度的性质和成本将增加将其纳入主流实践的可能性。电流控制试验,ISRCTN12591717。于2016年7月29日注册。协议编号:31288:西北-Haydock研究伦理委员会,2016年6月20日,参考号:16 / NW / 0389。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号